<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012448308</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012448308</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacogenomics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacogenomic Applications in Oncology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Walko</surname>
<given-names>Christine M.</given-names>
</name>
<degrees>PharmD, BCOP</degrees>
<xref ref-type="aff" rid="aff1-0897190012448308">1</xref>
<xref ref-type="aff" rid="aff2-0897190012448308">2</xref>
<xref ref-type="corresp" rid="corresp1-0897190012448308"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ikediobi</surname>
<given-names>Ogechi</given-names>
</name>
<degrees>PharmD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0897190012448308">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0897190012448308"><label>1</label>UNC School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC, USA</aff>
<aff id="aff2-0897190012448308"><label>2</label>Institute of Pharmacogenomics and Individualized Therapy, Chapel Hill, NC, USA</aff>
<aff id="aff3-0897190012448308"><label>3</label>University of California, San Francisco, San Francisco, CA, USA</aff>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name>
<surname>Saltiel</surname>
<given-names>Manny</given-names>
</name>
<degrees>PharmD, FASHP, FCCP</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0897190012448308">Christine M. Walko, Division of Pharmacotherapy and Experimental Therapeutics, Institute of Pharmacogenomics and Individualized Therapy, Campus Box #7569, 3203 Kerr Hall, Chapel Hill, NC 27599-7569, USA Email: <email>cwalko@email.unc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>4</issue>
<fpage>439</fpage>
<lpage>446</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Oncology chemotherapeutics frequently exhibit a narrow therapeutic index, further complicated by the serious nature of dosing either too high (dangerous toxicities) or too low (loss of antitumor benefits). This underscores the need for optimal individualized drug selection and dosing, especially with agents that have wide interpatient variability. Pharmacogenomic assessment of drug metabolizing enzymes can improve the ability to optimally dose patients being treated with certain agents such as 6-mercaptopurine, irinotecan, tamoxifen, and flurouracil. Two of these agents (6-mercaptopurine and irinotecan) already have mention of pharmacogenomic testing in their FDA approved package inserts. Ongoing retrospective and prospective trials will help to further optimize the place in clinical practice for not only performing these pharmacogenomic assessments but, more importantly, how the results should be incorporated into therapy dosing decisions for patients.</p>
</abstract>
<kwd-group>
<kwd>Pharmacogenomics</kwd>
<kwd>oncology</kwd>
<kwd>6-mercaptopurine</kwd>
<kwd>irinotecan</kwd>
<kwd>tamoxifen</kwd>
<kwd>and flurouracil</kwd>
<kwd>TPMT</kwd>
<kwd>UGT1A1</kwd>
<kwd>CYP2D6</kwd>
<kwd>and DPD</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The goal of pharmacogenomics is to utilize an individual's genetic makeup to predict appropriate treatment. Hematology and oncology is one of the most exciting specialties in medicine to demonstrate the concepts and importance of pharmacogenomics. Traditionally, most cytotoxic chemotherapy dosing is calculated with the use of body weight and surface area. However, patients with inherited deficiencies in enzymes responsible for drug metabolism and disposition can have severe toxicities at these traditional doses. Thiopurines are a class of drugs used in the treatment of leukemia and are metabolized by the enzyme thiopurine <italic>S</italic>-methyltransferase (TPMT). Patients who have a deficiency in TPMT can have greatly elevated concentrations of active drug metabolites and are at risk of life-threatening, drug-induced myelosuppression. On the other hand, patients with increased enzymatic activity may be at risk of treatment failure resulting in cancer progression. Other examples of enzyme deficiencies and the drugs they metabolize include uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) and irinotecan, cytochrome P450 2D6 (CYP2D6) and tamoxifen, and dihydropyrimidine dehydrogenase (DPD) and 5-fluorouracil (5-FU), all of which will be discussed in turn.</p>
<sec id="section1-0897190012448308">
<title>TPMT and 6-Mercaptopurine</title>
<p>Thiopurine drugs, such as 6-mercaptopurine, are purine antimetabolites used clinically to treat leukemias and are metabolized by the enzyme TPMT.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448308">1</xref>
</sup> Interindividual variability in the TPMT activity in red blood cells (RBCs) was demonstrated to be a heritable autosomal codominant trait in exploratory studies.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448308">1</xref>
</sup> Over 11% of the population was found to have a coding nucleotide polymorphism, which is associated with low TPMT activity. More than 10% of the patients were found heterozygous and only 0.3% of the population was homozygous.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448308">1</xref>,<xref ref-type="bibr" rid="bibr2-0897190012448308">2</xref>
</sup> The clinical importance of this variation was realized when patients who experienced severe hematologic toxicity from thiopurine therapy were found to have low TPMP activity and elevated concentration of mercaptopurine metabolites.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012448308">3</xref>,<xref ref-type="bibr" rid="bibr4-0897190012448308">4</xref>
</sup>
</p>
<p>TPMT is a cytosolic enzyme that preferentially catalyzes the <italic>S</italic>-methylation of aromatic and heterocyclic thio compounds such as 6-MP. 6-MP is an inactive prodrug and requires metabolism to 6-thioguanine (6-TG), which exerts cytotoxicity by incorporation into DNA and RNA.<sup>
<xref ref-type="bibr" rid="bibr5-0897190012448308">5</xref>
</sup> 6-MP undergoes activation in a multienzymatic process to form 6-TG. Alternatively, 6-MP can undergo inactivation by <italic>S</italic>-methylation by TPMT or oxidation to thiouric acid by xanthine oxidase. However, hematopoietic cells (such as RBCs and leukocytes) do not have measurable xanthine oxidase activity, leaving TPMT as the major enzyme responsible for 6-MP inactivation.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012448308">6</xref>
</sup> In the absence of TPMT, 6-MP is metabolized in hematopoietic cells preferentially to produce high levels of 6-TG, which has a potent bone marrow suppressive activity, leading to exaggerated toxicities.</p>
<p>It is important to recognize such individuals both to avoid fatal bone marrow failure through inadvertent overdose and to ensure that an adequate drug effect can be achieved at a reduced dose.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012448308">4</xref>,<xref ref-type="bibr" rid="bibr7-0897190012448308">7</xref>
</sup> The potential benefit of testing TPMT activity to adjust the dose of 6-MP was demonstrated in a 6-year-old patient with acute lymphoblastic leukemia (ALL).<sup>
<xref ref-type="bibr" rid="bibr8-0897190012448308">8</xref>
</sup> After receiving a standard dose of 6-MP for the postremission therapy, the patient developed severe myelosuppression requiring a discontinuation of her treatment regimen. Interestingly, she was found to have 7× the population median value of 6-TG in her RBCs. Subsequent therapy with 6% of the standard 6-MP dosage allowed her to complete the potentially curative regimen without further toxicity.</p>
<p>Since measurements of TPMT activity and the RBC 6-TG levels are not clinically feasible assays, genetic testing was developed to provide greater convenience and better reproducibility. This test evaluates 3 different variant alleles <italic>TPMT*2</italic>, <italic>TPMT*3A</italic>, and <italic>TPMT*3C</italic>, which account for 95% of all the dysfunctional <italic>TPMT</italic> alleles detected. Importantly, there is also a high concordance between the measured TPMT activity and the incidence of these polymorphisms.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012448308">9</xref>,<xref ref-type="bibr" rid="bibr10-0897190012448308">10</xref>
</sup> The genotyping for common <italic>TPMT</italic> alleles have shown to identify patients at risk of severe 6-MP toxicity such that TPMT genotyping can be integrated into the clinical management of patients undergoing 6-MP treatment.<sup>
<xref ref-type="bibr" rid="bibr11-0897190012448308">11</xref>
</sup> In July 2003, an advisory subcommittee of the Food and Drug Administration (FDA) Center for Drug Evaluation and Research met to consider the role of TPMT genotyping in the administration of 6-MP treatment to pediatric leukemia patients. Even though comprehensive evaluation of the clinical benefit and cost-effectiveness of screening strategies with this test was not completed, the FDA decided that the evidence was sufficient to indicate benefit and to warrant informing prescribers, pharmacists, and patients of the availability of TPMT genotyping tests and their possible role in the selection and dosing of 6-MP. There is now an FDA-approved genetic test (DNA based) to determine which patients would be likely to experience severe myelosuppression prior to the administration of 6-MP.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012448308">12</xref>
</sup> However, in a recent cost-effectiveness analysis from a health care system perspective comparing costs and consequences over 3 months to evaluate the impact of TPMT tests on preventing myelosuppression and improving survival in pediatric patients with ALL receiving 6-MP, screening for TPMT mutations using the genotype testing prior to the administration of 6-MP was not found to be cost effective.<sup>
<xref ref-type="bibr" rid="bibr13-0897190012448308">13</xref>
</sup> In addition, not all patients who develop severe myelosuppression on 6-MP therapy have mutant TPMT, suggesting additional pathways responsible for this toxicity.</p>
<p>In summary, measurement of TPMT genotypes and/or TPMT enzyme activity before instituting 6-MP may help prevent toxicity by identifying individuals with low or absent TPMT enzyme activity. Despite the usefulness of the TPMT genotyping test, it is recommended that clinicians monitor complete blood count (CBC) and liver function tests as well as clinical status routinely in patients undergoing 6-MP therapy. In addition, a normal TPMT screening test should not preclude this routine clinical assessment.</p>
</sec>
<sec id="section2-0897190012448308">
<title>UGT1A1 and Irinotecan</title>
<p>Irinotecan is a topoisomerase I inhibitor used in combination with 5-FU as the first-line therapy for the treatment of metastatic colorectal cancer.<sup>
<xref ref-type="bibr" rid="bibr14-0897190012448308">14</xref>
</sup> Irinotecan is metabolized to its active metabolite, SN-38, which is 1000× more potent than the parent drug.<sup>
<xref ref-type="bibr" rid="bibr15-0897190012448308">15</xref>
</sup> SN-38 is inactivated by a polymorphic hepatic enzyme UGT1A1.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012448308">16</xref>
</sup> It has been observed that human liver samples harboring a dinucleotide repeat sequence (7 TA repeats or *28) in the UGT1A1 promoter have reduced metabolism of SN-38.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012448308">16</xref>
</sup> Patients with the 7 TA repeats (*28) of UGT1A1 have an increased risk of severe neutropenia, severe diarrhea, and death than patients without the polymorphism.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012448308">17</xref>
</sup>
</p>
<p>Approximately 10% of the North American population is homozygous for the <italic>UGT1A1*28</italic> allele (which is responsible for Gilbert's syndrome); an additional 40% are heterozygotes.<sup>
<xref ref-type="bibr" rid="bibr18-0897190012448308">18</xref>
</sup> In November 2004, the FDA Advisory Committee on Pharmaceutical Sciences considered the findings of several pharmacogenetic trials that had assessed the association between <italic>UGT1A1*28</italic> genotype and irinotecan-induced toxicities in patients who were homozygous for the <italic>UGT1A1*28</italic>/<italic>*28</italic> genotype.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012448308">17</xref>,<xref ref-type="bibr" rid="bibr19-0897190012448308">19</xref>
</sup> These studies suggested that the homozygotes for the <italic>UGT1A1*28/*28</italic> genotype causing UGT1A1 underexpression could be associated with an increased severity of irinotecan-induced diarrhea and neutropenia and decreased conversion of SN-38 to SN-38G.<sup>
<xref ref-type="bibr" rid="bibr14-0897190012448308">14</xref>,<xref ref-type="bibr" rid="bibr16-0897190012448308">16</xref>,<xref ref-type="bibr" rid="bibr17-0897190012448308">17</xref>,<xref ref-type="bibr" rid="bibr19-0897190012448308">19</xref>,<xref ref-type="bibr" rid="bibr22-0897190012448308">22</xref>
</sup> Based on these findings, in July 2005, the FDA advised to amend the product information for the drug to include the association between the <italic>UGT1A1*28</italic> genotype and hematologic toxicity and to recommend that patients with the <italic>UGT1A1*28/*28</italic> genotype receive a lower starting dose of irinotecan. In August 2005, the FDA approved a diagnostic test for the <italic>UGT1A1*28</italic> genotype (ie, Invader UGT1A1 Molecular Assay; Third Wave Technologies, Inc, Madison, Wisconsin).</p>
<p>More recent data indicate that the association between the <italic>UGT1A1*28</italic> genotype and irinotecan-induced neutropenia is dose dependent. A meta-analysis showed that even though the inheritance of <italic>UGT1A1*28/*28</italic> was associated with an increased risk of neutropenia at all doses, the relative risk of neutropenia at doses ≥250 mg/m<sup>2</sup> was significantly higher (risk ratio [RR]: 7.0, 95% confidence interval [CI]: 3.10-16.78) than that for the lower doses (80-145 mg/m<sup>2</sup> weekly, RR: 2.43, 95% CI: 1.34-4.39).<sup>
<xref ref-type="bibr" rid="bibr23-0897190012448308">23</xref>
</sup> This dose dependency on the risk of neutropenia could be explained by the relative extent of glucuronidation of SN-38 active metabolite. Similarly, the risk of severe diarrhea at medium and high doses of irinotecan was higher among patients with a <italic>UGT1A1*28/*28</italic> genotype than among those with either <italic>UGT1A1*1/*1</italic> or <italic>UGT1A1*1/*28</italic> genotypes.<sup>
<xref ref-type="bibr" rid="bibr24-0897190012448308">24</xref>
</sup> This increased risk of diarrhea in patients carrying <italic>UGT1A1*28</italic> alleles was not apparent with lower doses (&lt;125 mg/m<sup>2</sup>). In an evidence-based review, the quality of evidence on the analytical as well as clinical validity of current UGT1A1 testing methods was found to be adequate for severe toxicities such as neutropenia and diarrhea as stratified by <italic>UGT1A1</italic> common genotypes.<sup>
<xref ref-type="bibr" rid="bibr25-0897190012448308">25</xref>
</sup> The strongest association for a clinical end point was severe neutropenia as patients homozygous for the *28 allele were 3.5 times more likely to develop severe neutropenia compared with individuals with the wild-type genotype (RR 3.51; 95% CI: 2.03-6.07). The cost-effectiveness of the UGT1A1*28 genotyping has also been demonstrated primarily for caucasian populations, however, there is a dearth of information on the utility of the test for Asian populations.<sup>
<xref ref-type="bibr" rid="bibr26-0897190012448308">26</xref>
</sup>
</p>
<p>Despite strong evidence to support the use of UGT1A1 genotyping, routine use of this assay in all patients who are to receive irinotecan is not widely accepted. In addition, there are no current guidelines on how to dose the homozygous and heterozygous patients for the <italic>UGT1A1*28</italic> allele/alleles. Therefore, additional clinical studies focusing on these key questions will facilitate implementation of UGT1A1 genotyping into clinical practice.</p>
</sec>
<sec id="section3-0897190012448308">
<title>CYP2D6 and TAMOXIFEN Metabolism</title>
<p>Tamoxifen is a selective estrogen receptor modulator that is used in the treatment of endocrine receptor–positive breast cancer both in the localized and metastatic settings. It is also approved for use for prevention of breast cancer in high-risk women. It is the preferred agent for premenopausal women and a treatment option, instead of an aromatase inhibitor, for postmenopausal women. The low cost of tamoxifen, especially compared with the more expensive aromatase inhibitors, also makes tamoxifen an important agent worldwide. Tamoxifen exerts its mechanism of action in breast cancer cells through inhibition of the estrogen receptor (ER) on the tumor, however, approximately one third of patients with ER-positive breast cancer who would be expected to respond to tamoxifen do not.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012448308">27</xref>,<xref ref-type="bibr" rid="bibr28-0897190012448308">28</xref>
</sup> This may be explained by genomic alterations in the drug-metabolizing enzymes involved in tamoxifen activation and excretion.</p>
<p>Tamoxifen is extensively metabolized to several primary and secondary metabolites with varying degrees of hormonal activity. The majority of tamoxifen is converted to <italic>N</italic>-desmethyltamoxifen primarily via CYP3A4/5 which is then further converted to the major active metabolite, endoxifen (4-hydroxy-<italic>N</italic>-desmethyltamoxifen) via CYP2D6.<sup>
<xref ref-type="bibr" rid="bibr29-0897190012448308">29</xref>
</sup> The antiestrogen effects of endoxifen appear to be concentration dependent with suggestion of a possible threshold that must be reached for optimal effect.<sup>
<xref ref-type="bibr" rid="bibr30-0897190012448308">30</xref>,<xref ref-type="bibr" rid="bibr31-0897190012448308">31</xref>
</sup> The importance of this is underscored by the highly polymorphic nature of CYP2D6. More than 70 allelic CYP2D6 variants have been reported and vary in prevalence with respect to race and ethnicity.<sup>
<xref ref-type="bibr" rid="bibr32-0897190012448308">32</xref>
</sup> Based on CYP2D6 genotype, patients can be classified as ultrarapid metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM), or poor metabolizers (PM).<sup>
<xref ref-type="bibr" rid="bibr33-0897190012448308">33</xref>
</sup> Approximately 10% of the European/caucasian population may be classified as PM with the most common null allele being *4. In the East Asian population, the intermediate metabolizing allele *10 is found in 38% to 56% of the population while the *17 allele, another intermediate metabolizing allele, is found in up to 37% of African populations.<sup>
<xref ref-type="bibr" rid="bibr34-0897190012448308">34</xref>
</sup>
</p>
<p>Endoxifen concentrations vary with respect to CYP2D6 genotype with PM patients having lower concentrations than IMs, which are lower than EM and UM patients. Additionally, patients with an EM phenotype who are taking drugs that inhibit CYP2D6 had endoxifen concentrations 58% lower than those not taking these agents.<sup>
<xref ref-type="bibr" rid="bibr33-0897190012448308">33</xref>,<xref ref-type="bibr" rid="bibr35-0897190012448308">35</xref>,<xref ref-type="bibr" rid="bibr36-0897190012448308">36</xref>
</sup> Thus, lower CYP2D6 enzyme activity, either by genetics or drug interactions, can result in lower concentrations of the active tamoxifen metabolite, endoxifen.</p>
<p>The clinical relevance of these findings has been assessed in numerous studies with conflicting results. One of the largest retrospective trials assessed the relationship between CYP2D6 genotype and disease outcome in 1325 predominantly premenopausal caucasian women treated with adjuvant tamoxifen 20 mg daily. Tumor tissue or blood from the patients was assessed for the intermediate/reduced alleles *10 and *41 and the null alleles *3, *4, and *5. Nearly 46% of the population was classified as EM, 48% IM, and 5.9% PM. After 9 years of follow-up, the breast cancer recurrence rate for the EM, IM, and PM populations were 14.9%, 20.9%, and 29%, respectively. Compared with the EM patients, IM and PM patients had a statistically significant increased risk of disease recurrence (hazard ratio [HR]: 1.40; 95% CI: 1.04-1.90 for IM and HR 1.90, 95% CI: 1.10-3.28). There was no difference in overall survival between any of the groups, however. Limitations of this study include the predominantly caucasian population, lack of data on concurrent therapy with CYP2D6 inhibitors, and limited numbers of variant alleles.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448308">37</xref>
</sup>
</p>
<p>While 14 separate studies have found a positive relationship between CYP2D6 genotype and breast cancer outcomes in patients treated with tamoxifen, 15 studies have not supported the same association.<sup>
<xref ref-type="bibr" rid="bibr33-0897190012448308">33</xref>,<xref ref-type="bibr" rid="bibr38-0897190012448308">38</xref>,<xref ref-type="bibr" rid="bibr39-0897190012448308">39</xref>
</sup> Differences in study design between these trials may explain some of the differences in results. For example, across both the positive and negative trials, there is variability in the spectrum of <italic>CYP2D6</italic> alleles assessed, documentation of concurrent mediations that inhibit CYP2D6, and efficacy end points evaluated. Additionally, population characteristics including menopausal status and race/ethnicity may also affect study outcomes. The majority of studies have enrolled predominantly caucasian or Asian populations, with few studies assessing this relationship in African or African American populations. The menopausal status of patients enrolled, and subsequently the percentage of patients who receive aromatase inhibitors after tamoxifen, may also influence the efficacy results. Postmenopausal patients receiving tamoxifen who are classified as PMs who then go on to receive an aromatase inhibitor may have improved disease outcomes compared with a premenopausal PM patient who does not receive the aromatase inhibitor. Finally, the tamoxifen dose used in some of the trials was not consistent or reported.<sup>
<xref ref-type="bibr" rid="bibr33-0897190012448308">33</xref>
</sup> Patients classified as an IM who received 40 mg of tamoxifen have similar mean concentrations of endoxifen compared with EM patients receiving 20 mg.<sup>
<xref ref-type="bibr" rid="bibr40-0897190012448308">40</xref>
</sup> Future, prospective trials are needed to further elucidate the interaction of CYP2D6 and tamoxifen and its metabolites in breast cancer clinical outcomes. Trials assessing the role and potential threshold concentrations of tamoxifen and metabolites, additional drug metabolizing enzyme variability, and breast cancer tumor characteristics are underway.</p>
<p>Less debatable is the effect of drugs known to inhibit CYP2D6 on endoxifen concentrations. This has been investigated in several trials. In 158 patients with breast cancer receiving tamoxifen, 33 <italic>CYP2D6</italic> alleles and medication history was assessed. Endoxifen levels were analyzed after 4 months of tamoxifen therapy. The potent inhibitors paroxetine and fluoxetine significantly reduced endoxifen levels in EM patients similar to the concentrations found in PM patients. The weak inhibitors sertraline and citalopram caused a moderate decrease in endoxifen levels. No decrease was seen with venlafaxine.<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448308">41</xref>
</sup> A separate trial investigated the association between CYP2D6 phenotype, considering both genotype and presence or absence of concurrent CYP2D6 inhibitors, and clinical outcomes. In this trial, EM status (n = 115) was defined as absence of the CYP2D6*4 allele and no concurrent therapy with a CYP2D6 inhibitor. IM status (n = 40) was defined as either heterozygosity for <italic>CYP2D6*4</italic> and no concurrent therapy with a CYP2D6 inhibitor or patients who would be classified as an EM but who were taking a weak or moderate CYP2D6 inhibitor. PM status (n = 16) was defined as either homozygosity for the CYP2D6*4 allele, patients who would be classified as an IM but who were taking a weak or moderate CYP2D6 inhibitor or patients who would be classified as an EM but who were taking a strong CYP2D6 inhibitor. Weak or moderate inhibitors included sertraline, cimetadine, amiodarone, doxepin, ticlopidine, or haloperidol and strong inhibitors included fluoxetine and paroxetine. PM patients had shorter time to breast cancer recurrence (<italic>P</italic> = .007), lower relapse free survival (<italic>P</italic> = .005) and disease-free survival (<italic>P</italic> = .008) compared with EM patients. IM patients had lower relapse-free survival (<italic>P</italic> = .075) and disease-free survival (.097). Overall survival did not differ between the groups.<sup>
<xref ref-type="bibr" rid="bibr35-0897190012448308">35</xref>
</sup>
</p>
<p>Based on the above data, the American Society of Clinical Oncology does not recommend routine testing of postmenopausal women to select therapy between tamoxifen and an aromatase inhibitor. However, caution is recommended with concurrent CYP2D6 inhibitors (buproprion, paroxetine, and fluoxetine) in patients receiving tamoxifen and should ideally be avoided if possible.<sup>
<xref ref-type="bibr" rid="bibr42-0897190012448308">42</xref>
</sup> Although not officially discussed, in clinical practice, there may be some populations of patients in whom CYP2D6 testing may be beneficial such as a postmenopausal patient with high-risk breast cancer with poor bone density or who desires tamoxifen. Future trials are needed to assess whether threshold values for endoxifen concentrations exist and whether they differ between subtypes of breast cancer. If this is found to be true, then future dose escalation trials may be helpful in individualizing therapy for patients receiving tamoxifen. The value of individualized therapy in the ER-positive, nonmetastatic breast cancer setting is especially of importance, given the curable nature of the disease.</p>
</sec>
<sec id="section4-0897190012448308">
<title>5-FU and DPD</title>
<p>5-FU and the oral FU prodrug, capecitabine, are fluoropyrimidines frequently used as single or combination therapy, with either chemotherapy or radiation, for colorectal and head and neck cancers. FU is metabolized either by an anabolic pathway responsible for the drug’s cytotoxic effects or a catabolic pathway responsible for detoxification and elimination. The former pathway is mediated by thymidine phosphorylase (TP), which converts the parent FU into fluorodeoxyuridine, which is ultimately converted to an active metabolite, fluorodeoxyuridine monophosphate. FU cytotoxicity occurs primarily through the inhibition of thymidylate synthase (TS), the rate-limiting step in the synthesis of de novo thymidine which ultimately leads to the inhibition of DNA synthesis and repair. A second mechanism of action involves TP-mediated metabolism of FU to fluorouridine triphosphate, a false nucleotide, which can be incorporated into RNA and ultimately results in the inhibition of DNA synthesis and eventually apoptosis.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012448308">43</xref>,<xref ref-type="bibr" rid="bibr44-0897190012448308">44</xref>
</sup> Both TS and TP have been investigated as clinical biomarkers to predict response to FU with some evidence suggesting lower levels of these enzymes in tumors may lead to better clinical outcomes; however, conflicting evidence has limited their value in clinical practice.<sup>
<xref ref-type="bibr" rid="bibr45-0897190012448308">45</xref>
</sup>
</p>
<p>Detoxification and elimination of FU are mediated by the DPD enzyme which results in the formation of the inactive metabolites such as dihydrofluorouracil and ultimately fluoro-<italic>p</italic>-alanine, the latter of which is eliminated via the urine. This elimination route is the metabolite fate of approximately 85% of the FU initially delivered to humans.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012448308">43</xref>
</sup> Disruption in this elimination process, such as in patients with deficiency of the DPD enzyme, can result in increased toxicity manifested as severe gastrointestinal and hematologic effects. Over 30 single-nucleotide polymorphisms and deletion mutations have been identified within <italic>DPYD</italic>, the gene responsible for encoding the DPD enzyme. Although the majority of these mutations have no functional consequences, the <italic>DPYD*2A</italic> variant has been found in up to 50% of patients with partial or complete DPD deficiency.<sup>
<xref ref-type="bibr" rid="bibr48-0897190012448308">48</xref>,<xref ref-type="bibr" rid="bibr49-0897190012448308">49</xref>
</sup> The frequency of DPD deficiency differs across ethnic groups with differences in the definition of “deficiency” complicating comparison between studies. Early studies defined DPD deficiency as patients with levels in the lower 95th percentile, while other trials have used the lower 70th percentile, which would translate into 5% or less and 14% of the general population, respectively.<sup>
<xref ref-type="bibr" rid="bibr50-0897190012448308">50</xref>,<xref ref-type="bibr" rid="bibr51-0897190012448308">51</xref>
</sup>
</p>
<p>Several different assays have been utilized to determine partial or complete DPD deficiency. These include direct measure of catabolite formation from radiolabeled FU in patient peripheral blood mononuclear cells (gold standard), real-time quantitative polymerase chain reaction of DPD messenger RNA, measurement of uracil levels to determine DPD activity, and a radiolabeled uracil breath test. A confounding factor limiting translation into clinical practice is that not all genetic mutations in DPYP are translated into severe FU toxicity. Ideally, a clinical-based test would identify all patients with DPD deficiency who would experience toxicity so that the dose of FU could be decreased prior to exposing the patient to the drug, while also not decreasing the dose in patients who do not have the deficiency. Analysis with <italic>DPYD*2A</italic> alone or with other common variants yielded a sensitivity of 6.3% to 83% (median 30%) and specificity of 82% to 100% (median 99%). The positive predictive value or ability of the test to differentiate patients with a positive test who have DPD deficiency was 62% to 100% (median 85%) and the negative predictive value (ability to differentiate patients with a negative test who do not have DPD deficiency) was 85.6% to 94% (median 92%).<sup>
<xref ref-type="bibr" rid="bibr51-0897190012448308">51</xref>
</sup>
</p>
<p>The prospective value of identifying patients with altered DPD function and adjusting FU doses according to these results was assessed in 65 patients with head and neck cancer receiving FU with or without concurrent platinum therapy, paclitaxel, and/or radiation. DPD function was assessed by determining the U/UH2 plasma ratio and classified as non-, mildly, severely, or totally deficient. Patients classified as nondeficient received the standard dose of FU, while patients with decreased levels received dose-reduced FU proportional to their level of DPD deficiency. Patients were assessed for toxicity and efficacy and compared with a reference subset of 74 similar patients who did not receive DPD testing. Mild DPD deficiency was found in 48% of the study population and severe deficiency in 28%, which resulted in FU dose reductions ranging from 10% to 100%. Severe toxicities were seen in 6 (9%) of the 65 patients with none of the toxicities being life threatening or resulting in death. This compared favorably with the reference group in which 22% experienced severe toxicities with 13% life threatening and 1 toxic death. Additionally, although toxicity was decreased in the study group, no difference in response rate was seen between the 2 groups (78% in the study group and 79% in the reference group, <italic>P</italic> = .790).<sup>
<xref ref-type="bibr" rid="bibr52-0897190012448308">52</xref>
</sup> Although encouraging, it is important to consider the small sample size and single arm, noncomparison design of this study, and larger comparative trials are needed before this method is employed in standard clinical practice.</p>
<p>Until the value and safety of prospective DPD assessment and dose adjustment are determined, clinical practitioners can still utilize phenotype to individualize therapy. Pharmacokinetic adjustment to a desired exposure level is employed routinely with antibiotics with some data existing for certain chemotherapy agents as well. A correlation between FU toxicity and systemic exposure, as measured by area under the concentration time curve (AUC), has been consistently observed in numerous studies involving continuous infusion FU. In a randomized, prospectively controlled phase III trial of 208 patients with metastatic colorectal cancer, Gamelin and colleagues compared conventional FU dosing with pharmacokinetic dose adjustment. In the latter arm, pharmacokinetic monitoring was employed for FU delivery targeted to a previously defined target AUC<sub>0-8 h</sub> plasma concentration range of 20 to 24 mg/L per h with the aid of a dosing nomogram. A significantly higher overall response rate of 33.7% was achieved in the dose-adapted arm compared with 18.3% in the conventionally dosed arm (<italic>P</italic> = .004). Median overall survival was also prolonged in the dose-adapted arm (22 months vs 16 months), while the frequency of toxic events was reduced in the dose-adapted arm (<italic>P</italic> = .003).<sup>
<xref ref-type="bibr" rid="bibr53-0897190012448308">53</xref>
</sup> Future studies are underway to determine the value of this dose targeting in more standard dosing regimens used in both colorectal and head and neck cancer, along with the ability to use prospective DPD assessment to direct therapy.</p>
<p>Interpatient differences in drug metabolism between individuals, such as TPMP, UGT1A1*28, CYP2D6, and DPD, offer one method of predicting toxicity and drug response. However, with the increasing list of targeted therapies, drug efficacy can also depend upon tumor expression of a particular target or somatic mutation within the tumor activating a particular growth pathway. Numerous targeted therapies have been approved with indications for a specific tumor target or somatic mutation and are listed in <xref ref-type="table" rid="table1-0897190012448308">Table 1</xref>. Together, germ line and somatic tumor mutations are increasing the ability to provide our patients with individualized therapy designed to minimize toxicity while also maximizing efficacy.</p>
<table-wrap id="table1-0897190012448308" position="float">
<label>Table 1.</label>
<caption>
<p>FDA Approved Targeted Therapies</p>
</caption>
<graphic alternate-form-of="table1-0897190012448308" xlink:href="10.1177_0897190012448308-table1.tif"/>
<table>
<thead>
<tr>
<th>Drug name</th>
<th>Tumor target</th>
<th>Tumor type</th>
<th>FDA-approved indication<sup><xref ref-type="table-fn" rid="table-fn2-0897190012448308">a</xref></sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3">Cetuximab (Erbitux<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr54-0897190012448308">54</xref>
</sup>
</td>
<td rowspan="3">EGFR</td>
<td rowspan="3">Colorectal </td>
<td>Used in combination with irinotecan in metastatic colorectal carcinoma patients expressing EGFR and refractory to irinotecan-based chemotherapy.</td>
</tr>
<tr>
<td>Used as a single agent in patients who are intolerant to irinotecan-based chemotherapy.</td>
</tr>
<tr>
<td>Not recommended for colorectal carcinoma with KRAS mutations in codon 12 or 13.</td>
</tr>
<tr>
<td rowspan="2">Panitumumab (Vectibix<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr55-0897190012448308">55</xref>
</sup>
</td>
<td rowspan="2">EGFR</td>
<td rowspan="2">Colorectal </td>
<td>Single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. </td>
</tr>
<tr>
<td>Not recommended for colorectal carcinoma with KRAS mutations in codon 12 or 13.</td>
</tr>
<tr>
<td rowspan="3">Erlotinib (Tarceva<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr56-0897190012448308">56</xref>
</sup>
</td>
<td rowspan="3">Tyrosine kinase within EGFR</td>
<td rowspan="3">NSCLC, pancreatic</td>
<td>Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy.</td>
</tr>
<tr>
<td>Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen</td>
</tr>
<tr>
<td>Combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer</td>
</tr>
<tr>
<td rowspan="3">Imatinib (Gleevec<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr57-0897190012448308">57</xref>
</sup>
</td>
<td rowspan="3">BCR-ABL tyrosine kinase, c-KIT</td>
<td rowspan="3">CML</td>
<td>Treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive CML in chronic phase as well as in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy. </td>
</tr>
<tr>
<td>Treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant</td>
</tr>
<tr>
<td>Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant GIST</td>
</tr>
<tr>
<td>Nilotinib (Tasigna<sup>
<sup>®</sup>
</sup>)<sup>
<xref ref-type="bibr" rid="bibr58-0897190012448308">58</xref>
</sup>
</td>
<td>BCR-ABL tyrosine kinase</td>
<td>CML</td>
<td>Treatment of chronic phase and accelerated phase Philadelphia chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib</td>
</tr>
<tr>
<td rowspan="3">Dasatinib (Sprycel<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr59-0897190012448308">59</xref>
</sup>
</td>
<td rowspan="3">BCR-ABL tyrosine kinase</td>
<td rowspan="3">CML, ALL</td>
<td>Newly diagnosed adults with Philadelphia chromosome-positive CML in chronic phase. </td>
</tr>
<tr>
<td>Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.</td>
</tr>
<tr>
<td>Adults with Philadelphia chromosome-positive ALL with resistance or intolerance to prior therapy. </td>
</tr>
<tr>
<td rowspan="2">Lapatinib (Tykerb<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr60-0897190012448308">60</xref>
</sup>
</td>
<td rowspan="2">HER-2</td>
<td rowspan="2">Breast</td>
<td>Used in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER-2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. </td>
</tr>
<tr>
<td>Used in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated</td>
</tr>
<tr>
<td rowspan="2">Trastuzumab (Herceptin<sup>®</sup>)<sup>
<xref ref-type="bibr" rid="bibr61-0897190012448308">61</xref>
</sup>
</td>
<td rowspan="2">HER-2/neu</td>
<td rowspan="2">Breast</td>
<td>Treatment of HER2 overexpressing breast cancer </td>
</tr>
<tr>
<td>Treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma </td>
</tr>
<tr>
<td>Vemurafenib (Zelboraf<sup>
<sup>®</sup>
</sup>)<sup>
<xref ref-type="bibr" rid="bibr62-0897190012448308">62</xref>
</sup>
</td>
<td>BRAF serine-threonine kinase</td>
<td>Melanoma</td>
<td>Treatment of patients with unresectable or metastatic melanoma with BRAF<sup>V600E </sup>mutation as detected by an FDA-approved test.</td>
</tr>
<tr>
<td>Crizotinib (Xalkori)<sup>
<xref ref-type="bibr" rid="bibr63-0897190012448308">63</xref>
</sup>
</td>
<td>ALK, c-Met/HGFR</td>
<td>Anaplastic large cell lymphoma, inflammatory myofibroblastic tumors, neuroblastomas, and NSCLC</td>
<td>Treatment of patients with locally advanced or metastatic NSCLC that is ALK positive as detected by FDA-approved test. </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012448308">
<p>Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; HER-2, human epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; HGFR, hepatocyte growth factor receptor; GIST, gastrointestinal stromal tumors; FDA, Food and Drug Administration.</p>
</fn>
<fn id="table-fn2-0897190012448308">
<p>
<sup>a</sup> <ext-link ext-link-type="uri" xlink:href="www.fda.gov">www.fda.gov</ext-link>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012448308">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012448308">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012448308">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinshilboum</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Sladek</surname>
<given-names>SL</given-names>
</name>
</person-group>. <article-title>Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity</article-title>. <source>Am J Hum Genet</source>. <year>1980</year>;<volume>32</volume>(<issue>5</issue>):<fpage>651</fpage>–<lpage>662</lpage>.</citation>
</ref>
<ref id="bibr2-0897190012448308">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLeod</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Relling</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group> <article-title>Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>1995</year>;<volume>85</volume>(<issue>7</issue>):<fpage>1897</fpage>–<lpage>1902</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012448308">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lennard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Van Loon</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lilleyman</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group> <article-title>Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations</article-title>. <source>Clin Pharmacol Ther</source>. <year>1987</year>;<volume>41</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012448308">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lennard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Van Loon</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>RM</given-names>
</name>
</person-group>. <article-title>Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism</article-title>. <source>Clin Pharmacol Ther</source>. <year>1989</year>;<volume>46</volume>(<issue>2</issue>):<fpage>149</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr5-0897190012448308">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elion</surname>
<given-names>GB</given-names>
</name>
</person-group>. <article-title>The purine path to chemotherapy</article-title>. <source>Science</source>. <year>1989</year>;<volume>244</volume>(<issue>4900</issue>):<fpage>41</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012448308">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parks</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Granger</surname>
<given-names>DN</given-names>
</name>
</person-group>. <article-title>Xanthine oxidase: biochemistry, distribution and physiology</article-title>. <source>Acta Physiol Scand Suppl</source>. <year>1986</year>;<volume>548</volume>:<fpage>87</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012448308">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lennard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Nicole</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia</article-title>. <source>Arch Dis Child</source>. <year>1993</year>;<volume>69</volume>(<issue>5</issue>):<fpage>577</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr8-0897190012448308">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Horner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>YQ</given-names>
</name>
<etal/>
</person-group> <article-title>Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia</article-title>. <source>J Pediatr</source>. <year>1991</year>;<volume>119</volume>(<issue>6</issue>):<fpage>985</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr9-0897190012448308">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaeffeler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brockmeier</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants</article-title>. <source>Pharmacogenetics</source>. <year>2004</year>;<volume>14</volume>(<issue>7</issue>):<fpage>407</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012448308">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yates</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Krynetski</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Loennechen</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance</article-title>. <source>Ann Intern Med</source>. <year>1997</year>;<volume>126</volume>(<issue>8</issue>):<fpage>608</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012448308">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Hon</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Bomgaars</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine</article-title>. <source>J Clin Oncol</source>. <year>2001</year>;<volume>19</volume>(<issue>8</issue>):<fpage>2293</fpage>–<lpage>2301</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012448308">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goetz</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Ames</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Weinshilboum</surname>
<given-names>RM</given-names>
</name>
</person-group>. <article-title>Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model</article-title>. <source>Mayo Clin Proc</source>. <year>2004</year>;<volume>79</volume>(<issue>3</issue>):<fpage>376</fpage>–<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012448308">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donnan</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ungar</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia</article-title>. <source>Pediatr Blood Cancer</source>. <year>2011</year>;<volume>57</volume>(<issue>2</issue>):<fpage>231</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012448308">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathijssen</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Karlsson</surname>
<given-names>MO</given-names>
</name>
<etal/>
</person-group> <article-title>Irinotecan pathway genotype analysis to predict pharmacokinetics</article-title>. <source>Clin Cancer Res</source>. <year>2003</year>;<volume>9</volume>(<issue>9</issue>):<fpage>3246</fpage>–<lpage>3253</lpage>.</citation>
</ref>
<ref id="bibr15-0897190012448308">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaneda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse</article-title>. <source>Cancer Res</source>. <year>1990</year>;<volume>50</volume>(<issue>6</issue>):<fpage>1715</fpage>–<lpage>1720</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012448308">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iyer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>King</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Whitington</surname>
<given-names>PF</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes</article-title>. <source>J Clin Invest</source>. <year>1998</year>;<volume>101</volume>(<issue>4</issue>):<fpage>847</fpage>–<lpage>854</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012448308">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ando</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Saka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>(<issue>24</issue>):<fpage>6921</fpage>–<lpage>6926</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012448308">
<label>18</label>
<citation citation-type="book">
<collab collab-type="author">Camptosar (irinotecan) [package insert]</collab>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Pfizer</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr19-0897190012448308">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Innocenti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Undevia</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan</article-title>. <source>J Clin Oncol</source>. <year>2004</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1382</fpage>–<lpage>1388</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012448308">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcuello</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Altes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Menoyo</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer</article-title>. <source>Br J Cancer</source>. <year>2004</year>;<volume>91</volume>(<issue>4</issue>):<fpage>678</fpage>–<lpage>682</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012448308">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouits</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Boisdron-Celle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dumont</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients</article-title>. <source>Clin Cancer Res</source>. <year>2004</year>;<volume>10</volume>(<issue>15</issue>):<fpage>5151</fpage>–<lpage>5159</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012448308">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group> <article-title>Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk</article-title>. <source>Clin Cancer Res</source>. <year>2010</year>;<volume>16</volume>(<issue>15</issue>):<fpage>3832</fpage>–<lpage>3842</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012448308">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Saeki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer</article-title>. <source>Clin Pharmacol Ther</source>. <year>2004</year>;<volume>75</volume>(<issue>6</issue>):<fpage>501</fpage>–<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012448308">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>YS</given-names>
</name>
</person-group>. <article-title>Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis</article-title>. <source>Eur J Cancer</source>. <year>2010</year>;<volume>46</volume>(<issue>10</issue>):<fpage>1856</fpage>–<lpage>1865</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012448308">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palomaki</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>MP</given-names>
</name>
<etal/>
</person-group> <article-title>Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review</article-title>. <source>Genet Med</source>. <year>2009</year>;<volume>11</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012448308">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obradovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mrhar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kos</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer</article-title>. <source>Pharmacogenomics</source>. <year>2008</year>;<volume>9</volume>(<issue>5</issue>):<fpage>539</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr27-0897190012448308">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osborne</surname>
<given-names>CK</given-names>
</name>
</person-group>. <article-title>Tamoxifen in the treatment of breast cancer</article-title>. <source>N Eng J Med</source>. <year>1998</year>;<volume>339</volume>:<fpage>1609</fpage>–<lpage>1618</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012448308">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dellapasqua</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colleoni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gelber</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Adjuvant endocrine therapy for premenopausal women with early breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>:<fpage>1736</fpage>–<lpage>1750</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012448308">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desta</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Soukhova</surname>
<given-names>NV</given-names>
</name>
<etal/>
</person-group> <article-title>Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2004</year>;<volume>310</volume>(<issue>3</issue>):<fpage>1062</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012448308">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hawse</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>(<issue>5</issue>):<fpage>1722</fpage>–<lpage>1727</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012448308">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madlensky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tchu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes</article-title>. <source>Clin Pharmacol Ther</source>. <year>2011</year>;<volume>89</volume>(<issue>5</issue>):<fpage>718</fpage>–<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr32-0897190012448308">
<label>32</label>
<citation citation-type="web">
<collab collab-type="author">PharmGKB (number of alleles)</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.pharmgkb.org">http://www.pharmgkb.org</ext-link>. <comment>Accessed on August 26, 2011</comment>.</citation>
</ref>
<ref id="bibr33-0897190012448308">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoskins</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>McLeod</surname>
<given-names>HL</given-names>
</name>
</person-group>. <article-title>CYP2D6 and tamoxifen: DNA matters in breast cancer</article-title>. <source>Nature Rev Cancer</source>. <year>2009</year>;<volume>9</volume>(<issue>8</issue>):<fpage>576</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr34-0897190012448308">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradford</surname>
<given-names>LD</given-names>
</name>
</person-group>. <article-title>CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendents</article-title>. <source>Pharmacogenomics</source>. <year>2002</year>;<volume>3</volume>(<issue>2</issue>):<fpage>229</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr35-0897190012448308">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Desta</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sterns</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment</article-title>. <source>J Natl Cancer Inst</source>. <year>2005</year>;<volume>97</volume>(<issue>1</issue>):<fpage>30</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012448308">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stearns</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Rae</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine</article-title>. <source>J Natl Cancer Inst</source>. <year>2003</year>;<volume>95</volume>(<issue>23</issue>):<fpage>1758</fpage>–<lpage>1764</lpage>.</citation>
</ref>
<ref id="bibr37-0897190012448308">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroth</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Hamann</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group> <article-title>Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>(<issue>13</issue>):<fpage>1429</fpage>–<lpage>1436</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012448308">
<label>38</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Leyland-Jones</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bouzyk</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial</article-title>. <comment>Presented at the 33 rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-12, 2010 (Abstr S1-8)</comment>.</citation>
</ref>
<ref id="bibr39-0897190012448308">
<label>39</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rae</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Drury</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>DF</given-names>
</name>
<etal/>
</person-group> <article-title>Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial</article-title>. <comment>Presented at the 33 rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-12, 2010 (Abstr S1-7)</comment>.</citation>
</ref>
<ref id="bibr40-0897190012448308">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irvin</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Walko</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Weck</surname>
<given-names>KE</given-names>
</name>
<etal/>
</person-group> <article-title>Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a mutlicenter study</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>24</issue>):<fpage>3232</fpage>–<lpage>3239</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012448308">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borges</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Desta</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implications for optimization of breast cancer treatment</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>80</volume>(<issue>1</issue>):<fpage>61</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr42-0897190012448308">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burstein</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Prestrud</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Seidenfeld</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>(<issue>23</issue>):<fpage>3784</fpage>–<lpage>3796</lpage>.</citation>
</ref>
<ref id="bibr43-0897190012448308">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rich</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Shepard</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Mosley</surname>
<given-names>ST</given-names>
</name>
</person-group>. <article-title>Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy</article-title>. <source>J Clin Oncol</source>. <year>2004</year>;<volume>22</volume>(<issue>11</issue>):<fpage>2214</fpage>–<lpage>2232</lpage>.</citation>
</ref>
<ref id="bibr44-0897190012448308">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobrero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guglielmi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grossi</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy</article-title>. <source>Semin Oncol</source>. <year>2000</year>;<volume>27</volume>(<issue>suppl 10</issue>):<fpage>72</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr45-0897190012448308">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matakidou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Houlston</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis</article-title>. <source>J Clin Oncol</source>. <year>2004</year>;<volume>22</volume>(<issue>3</issue>):<fpage>529</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr46-0897190012448308">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metzger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Danenberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leichman</surname>
<given-names>CG</given-names>
</name>
<etal/>
</person-group> <article-title>High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil</article-title>. <source>Clin Cancer Res</source>. <year>1998</year>;<volume>4</volume>(<issue>10</issue>):<fpage>2371</fpage>–<lpage>2376</lpage>.</citation>
</ref>
<ref id="bibr47-0897190012448308">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhushan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McLeod</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Walko</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer</article-title>. <source>Clin Colorectal Cancer</source>. <year>2009</year>;<volume>8</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr48-0897190012448308">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>X</given-names>
</name>
<name>
<surname>McLeod</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>McMurrough</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity</article-title>. <source>J Clin Invest</source>. <year>1996</year>;<volume>98</volume>(<issue>3</issue>):<fpage>610</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr49-0897190012448308">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Kuilenburg</surname>
<given-names>ABP</given-names>
</name>
<name>
<surname>Vreken</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Abeling</surname>
<given-names>NGGM</given-names>
</name>
<etal/>
</person-group> <article-title>Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency</article-title>. <source>Hum Genet</source>. <year>1999</year>;<volume>104</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr50-0897190012448308">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Kuilenburg</surname>
<given-names>ABP</given-names>
</name>
<name>
<surname>Meinsma</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zoetekouw</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1 G&gt;A mutation</article-title>. <source>Int J Cancer</source>. <year>2002</year>;<volume>101</volume>(<issue>3</issue>):<fpage>253</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr51-0897190012448308">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>McLeod</surname>
<given-names>HL</given-names>
</name>
</person-group>. <article-title>Should DPD analysis be required prior to prescribing fluoropyrimidines?</article-title> <source>Eur J Cancer</source>. <year>2007</year>;<volume>43</volume>(<issue>6</issue>):<fpage>1011</fpage>–<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr52-0897190012448308">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Ciccolini</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blesius</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2011</year>;<volume>67</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr53-0897190012448308">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamelin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Delva</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>13</issue>):<fpage>2099</fpage>–<lpage>2105</lpage>.</citation>
</ref>
<ref id="bibr54-0897190012448308">
<label>54</label>
<citation citation-type="book">
<collab collab-type="author">Erbitux (cetuximab) [package insert]</collab>. <publisher-loc>Princeton, New Jersey</publisher-loc>: <publisher-name>Bristol Myers Squibb</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr55-0897190012448308">
<label>55</label>
<citation citation-type="book">
<collab collab-type="author">Vectibix (panitumumab) [package insert]</collab>. <publisher-loc>Thousand Oaks, California</publisher-loc>: <publisher-name>Amgen</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr56-0897190012448308">
<label>56</label>
<citation citation-type="book">
<collab collab-type="author">Tarceva (erlotinib) [package insert]</collab>. <publisher-loc>South San Francisco, California</publisher-loc>: <publisher-name>Genentech</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr57-0897190012448308">
<label>57</label>
<citation citation-type="book">
<collab collab-type="author">Gleevec (imatinib) [package insert]</collab>. <publisher-loc>East Hannover, New Jersey</publisher-loc>: <publisher-name>Novartis</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr58-0897190012448308">
<label>58</label>
<citation citation-type="book">
<collab collab-type="author">Tasigna (nilotinib) [package insert]</collab>. <publisher-loc>East Hannover, New Jersey</publisher-loc>: <publisher-name>Novartis</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr59-0897190012448308">
<label>59</label>
<citation citation-type="book">
<collab collab-type="author">Sprycel (dasatinib) [package insert]</collab>. <publisher-loc>Princeton, New Jersey</publisher-loc>: <publisher-name>Bristol Myers Squibb</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr60-0897190012448308">
<label>60</label>
<citation citation-type="book">
<collab collab-type="author">Tykerb (lapatinib) [package insert]</collab>. <publisher-loc>Research Triangle Park, North Carolina</publisher-loc>: <publisher-name>GlaxoSmithKline</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr61-0897190012448308">
<label>61</label>
<citation citation-type="book">
<collab collab-type="author">Herceptin (trastuzumab) [package insert]</collab>. <publisher-loc>South San Francisco, California</publisher-loc>: <publisher-name>Genentech</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr62-0897190012448308">
<label>62</label>
<citation citation-type="book">
<collab collab-type="author">Zelboraf (vemurafenib) [package insert]</collab>. <publisher-loc>South San Francisco, California</publisher-loc>: <publisher-name>Genentech</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr63-0897190012448308">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwak</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Bang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Camidge</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>18</issue>):<fpage>1693</fpage>–<lpage>1703</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>